Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/29/2005US20050287211 Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition
12/29/2005US20050287210 Also including 0.5-5 % polyvinylpyrrolidone and 5-40 % hydroxypropyl methylcellulose; administering an endothelial nitric oxide synthase agonist (an HMG-CoA reductase inhibitor) and a NO precursor (L-arginine hydrochloride) for cerebrovascular/cardiovascular disorders; anticholesterol agents
12/29/2005US20050287209 Directly compressible formulations of azithromycin
12/29/2005US20050287207 Solid preparation
12/29/2005US20050287206 Solubilized CoQ-10 and carnitine
12/29/2005US20050287205 Dietary supplement compositions
12/29/2005US20050287204 Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
12/29/2005US20050287203 Formulation comprising testosteron undecanoate and castor oil
12/29/2005US20050287200 Phospholipid gel compositions for drug delivery and methods of treating conditions using same
12/29/2005US20050287199 Therapeutic micro nutrient composition for lipolysis and drug delivery
12/29/2005US20050287196 Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release
12/29/2005US20050287195 Transdermal drug delivery systems
12/29/2005US20050287194 Permeation enhancing compositions for anticholinergic agents
12/29/2005US20050287189 Antitumor, anticancer agents; particles or coils or stents coated solid-phase agent comprising a binding agent comprising collagen are directed to target vasculature, such as the vasculature of solid tumor masses or aneurysms
12/29/2005US20050287188 Controlled release bioactive agent delivery device
12/29/2005US20050287184 Drug-delivery stent formulations for restenosis and vulnerable plaque
12/29/2005US20050287181 A mixture of propylene carbonate and glycerol formal in a ratio of 90:10-10:90 containing hydroxypropylmethylcellulose, a phospholipid and a fungicide; time-released agent; sustained'release; veterinary medicine; sustained release; topical, otic, and ophthalmic
12/29/2005US20050287180 Phospholipid compositions and methods for their preparation and use
12/29/2005US20050287179 Use of ethyl lactate as an excipient for pharmaceutical compositions
12/29/2005US20050287177 Pharmaceutical compositions
12/29/2005US20050287170 Subunit vaccine against West Nile viral infection
12/29/2005US20050287165 Meningococcal antigens
12/29/2005US20050287159 Treatment methods for eotaxin mediated inflammatory conditons
12/29/2005US20050287145 Compositions and methods for producing vascular occlusion
12/29/2005US20050287144 For the modulation of signal activities controlled by NF-kappa B-inducing kinase (NIK); cancer , rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, cardiac infarct, Alzheimer's disease, or atherosclerosis
12/29/2005US20050287142 Remedies or preventives for rheumatoid arthritis
12/29/2005US20050287139 Wound healing
12/29/2005US20050287135 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
12/29/2005US20050287134 use of a first drug operative to produce local capillary vasodilatation and/or augmented rate of bulk flow which is mixed with a fluid, then delivered subcutaneously or into deeper tissues by use of a hyperdermic needle or infiltration cannula
12/29/2005US20050287115 Treatment of ocular lesions
12/29/2005US20050287114 Water-soluble polymeric bone-targeting drug delivery system
12/29/2005US20050287113 two polymer molecules attached at a single site on a biomolecule; water soluble and have beneficial pharmacological properties, such as reduced immunogenicity and increased circulation time
12/29/2005US20050287111 Films for controlled cell growth and adhesion
12/29/2005US20050287109 N-halo-4-carboxybenzene sulfonamides; soap, lotion, wipe, or swab; minimal side effects; bactericide, pesticide, fungicide, deodorizing; also bovine teat cleaners, drugs for cultured fish, soap biocides, stain removal agents, and paint fungicides; paper mill sludge and sewerage treatment sludge
12/29/2005US20050287108 Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
12/29/2005US20050287086 Strip for covering teeth; containing a peroxy teeth whitening compound
12/29/2005US20050287080 Use of mometasone furoate for treating airway passage and lung disease
12/29/2005US20050287079 Combinations of formoterol and fluticasone propionate for asthma
12/29/2005US20050287077 Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
12/29/2005US20050287073 Carboranylporphyrins and uses thereof
12/29/2005US20050284812 Process for preparing water soluble diterpenes and their applications
12/29/2005DE60202483T2 Verfahren zur herstellung von l-ribavirin A process for the preparation of L-Ribavirin
12/29/2005DE20122504U1 Kristallines und reines Modafinil Crystalline and pure modafinil
12/29/2005DE19748040B4 Carbonsäurederivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate, die diese Verbindungen enthalten Carboxylic acid derivatives, processes for their preparation and pharmaceutical preparations containing these compounds
12/29/2005DE10228059B4 Verwendung von amphiphilen Nucleosid-Phosphonoameisensäure-Derivaten zur Behandlung von viralen Infektionskrankheiten Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases
12/29/2005DE102005027905A1 Combating stress states or nervous system or metabolic disorders, using glycine as neurotransmission modulator showing antistress, stress protective, nootropic and toxin binding actions
12/29/2005DE102005026380A1 Mittel zur Unterdrückung von Entzündungen, umfassend Zinkpyrrolidoncarboxylat Means for suppressing inflammation, comprising zinc pyrrolidonecarboxylate
12/29/2005DE102004028862A1 3-Aminoindazole 3 aminoindazoles
12/29/2005DE102004027924A1 Arzneiform, enthaltend den Wirkstoff Cholylsarcosin Dosage form comprising the active ingredient cholylsarcosine
12/29/2005DE102004027912A1 Substituierte Cyclopenten-Verbindungen Substituted cyclopentene compounds
12/29/2005DE102004027359A1 Pyridin-2-onverbindungen und deren Verwendung Pyridin-2-one compounds and use thereof
12/29/2005DE102004027358A1 Pyrimidinverbindungen und ihre Verwendung Pyrimidine compounds and their use
12/29/2005DE102004026309A1 Pharamzeutische Zusammensetzung zur Behandlung allergischer Erkrankungen, pathologischer Atemswegsveränderungen und von Krebs durch Modulation der Genexpression des Stat6 Pharamzeutische composition for the treatment of allergic diseases, pathological airway changes and cancer through modulation of gene expression of Stat6
12/29/2005DE102004025726A1 Verwendung eines spezifischen K252a-Derivats für die Behandlung von neurodegenerativen Erkrankungen, die durch eine pathologische Hyperphosphorylierung und eine Aggregation von Tau Proteinen in neurofibrillären Knäueln charakterisiert sind Using a specific K252a derivative for the treatment of neurodegenerative diseases, which are characterized by a pathological hyperphosphorylation of tau protein and aggregation in neurofibrillary tangles
12/29/2005CA2847677A1 Methods for treating conditions associated with masp-2 dependent complement activation
12/29/2005CA2612312A1 Topical compositions containing 5'-adenosine-diphosphate ribose
12/29/2005CA2579605A1 Topical compositions and methods for epithelial-related conditions
12/29/2005CA2573144A1 Methods for treating conditions associated with masp-2 dependent complement activation
12/29/2005CA2571679A1 Use of cb2 receptors agonists for the treatment of huntington's disease
12/29/2005CA2571614A1 Screening methods using c-abl, fyn and syk in combination with tau protein
12/29/2005CA2571501A1 Antimicrobial compositions and methods of use thereof
12/29/2005CA2571487A1 Pyrrazolo-pyrimidine derivatives
12/29/2005CA2571482A1 Pyk2 inhibitors for stimulation of osteoblast function
12/29/2005CA2571293A1 2-benzylaminodihydropteridinones, method for producing them and use thereof as drugs
12/29/2005CA2570709A1 Solid orally ingestible formulations of tetrodotoxin
12/29/2005CA2570534A1 Anti-parasitic uses of borinic acid complexes
12/29/2005CA2570531A1 Indoles useful in the treatment of inflammation
12/29/2005CA2570503A1 A method of improving the medical treatment of pain
12/29/2005CA2570477A1 Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones
12/29/2005CA2570472A1 Five-membered heterocycles useful as serine protease inhibitors
12/29/2005CA2570448A1 Methods and compositions for the treatment of pulmonary diseases
12/29/2005CA2570389A1 Treatments comprising strontium for rheumatic and arthritic diseases and pain
12/29/2005CA2570386A1 Methods of using albuterol and calcium activated potassium channel openers
12/29/2005CA2570365A1 Indoles useful in the treatment of inflammation
12/29/2005CA2570363A1 Indoles useful in the treatment of inflammation
12/29/2005CA2570264A1 3-aminoindazoles
12/29/2005CA2570248A1 Polycationic compounds and uses thereof
12/29/2005CA2570218A1 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
12/29/2005CA2570196A1 Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
12/29/2005CA2570184A1 Pharmaceutical compositions containing polyunsaturated fatty acid and at least one of an immunosuppressive agent or an antineoplastic agent
12/29/2005CA2570170A1 Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
12/29/2005CA2570158A1 Potent and selective inhibition by aurintricarboxylic acid
12/29/2005CA2570119A1 A pharmaceutical composition having prokinetic effect
12/29/2005CA2570075A1 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/29/2005CA2570065A1 Novel alkyl substituted piperidine derivatives as monoamine neurotransmitter re-uptake inhibitors
12/29/2005CA2570064A1 Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/29/2005CA2569986A1 Compositions and methods of use of dimer digallates
12/29/2005CA2569913A1 Amino-halogen-imidazopyridines as proton pump inhibitors
12/29/2005CA2569729A1 Peptidomimetic inhibitors of retroviral proteases and their use as antivirals
12/29/2005CA2569705A1 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
12/29/2005CA2569697A1 A pharmaceutical composition and its use
12/29/2005CA2569598A1 Novel cis-imidazolines
12/29/2005CA2569468A1 Ophthalmic formulations including selective alpha 1 antagonists
12/29/2005CA2569459A1 Glucagon receptor antagonists, preparation and therapeutic uses
12/29/2005CA2569368A1 Photochromic material comprising a proteorhodopsin apoprotein and retinal analog
12/29/2005CA2569310A1 Pharmaceutical compositions
12/29/2005CA2569152A1 Estrogen receptor modulators
12/29/2005CA2569125A1 Pyrrolopyridine derivatives and their use as crth2 antagonists
12/29/2005CA2569116A1 Gram-positive carbapenem antibacterials and processes for their preparation
12/29/2005CA2569112A1 Carbapenem antibacterials with gram-negative activity and processes for their preparation
1 ... 4418 4419 4420 4421 4422 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 4438 ... 7860